Skip Navigation

Cardiovascular Research 2001 51(2):265-274; doi:10.1016/S0008-6363(01)00294-2
© 2001 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Brar, B. K
Right arrow Articles by Latchman, D. S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brar, B. K
Right arrow Articles by Latchman, D. S
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2000, European Society of Cardiology

Cardiotrophin-1 can protect cardiac myocytes from injury when added both prior to simulated ischaemia and at reoxygenation

Bhawanjit K Brara, Anastasis Stephanoua, Zhihong Liaoa, Rhona M O'Learyc, Diane Pennicad, Derek M Yellonb and David S Latchmana,*

aInstitute of Child Health, University College London, London WC1N 1EH, UK
bHatter Institute of Cardiology, University College Hospitals, London, UK
cDepartment of Protein Sciences, Genentech Inc, South San Francisco, USA
dDepartment of Molecular Oncology, Genentech Inc, South San Francisco, USA

* Corresponding author. Tel.: +44-20-7905-2189; fax: +44-20-7242-8437 d.latchman{at}ich.ucl.ac.uk

Objective: The cytokine cardiotrophin-1 (CT-1) has previously been shown to protect cultured cardiocytes from cell death induced by serum removal or hypoxia when administered prior to the damaging stimulus. We wished to test whether a similar protective effect could be observed if CT-1 was added after the ischaemic period and to investigate the signalling pathways involved in the protective effect when CT-1 is given prior to or after ischaemia. Methods: We therefore examined the protective effect of CT-1 in cultured rat cardiocytes exposed to simulated ischaemia followed by reoxygenation when CT-1 was administered either prior to simulated ischaemia or at reoxygenation. Results: We show that CT-1 can exert a protective effect against the damaging effects of simulated ischaemia/reoxygenation both when added after the simulated ischaemia at reoxygenation (P<0.05 in trypan blue, TUNEL and annexin V assays) or when added prior to the simulated ischaemia (P<0.05). In both cases, these protective effects are blocked by an inhibitor of the p42/p44 MAPK pathway (P<0.05 in all assays). Conclusion: CT-1 can protect cardiac cells when added either prior to simulated ischaemia or at the time of reoxygenation following simulated ischaemia and these effects are dependent upon its ability to activate the p42/p44 MAPK pathway. Hence CT-1 may have therapeutic potential when added at the time of reperfusion following ischaemic damage.

KEYWORDS Apoptosis; Cell culture/isolation; Cytokines; Hypoxia/anoxia; Myocytes; Cardioplegia; Ischemia; Reperfusion


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
D. J. Hausenloy and D. M. Yellon
Cardioprotective growth factors
Cardiovasc Res, July 15, 2009; 83(2): 179 - 194.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.